Newswise — PLYMOUTH MEETING, PA [March 9, 2021] — New research in the March 2021 issue of JNCCN—Journal of the National Comprehensive Cancer Network from Mass General Hospital Cancer Center, Harvard Medical School, and Dana-Farber Cancer Institute finds muscle mass (quantity) correlated with survival, while muscle radiodensity (quality) was associated with symptom burden, healthcare use, and survival in patients with advanced cancer undergoing an unplanned hospitalization. The researchers also found nearly two-thirds of the patients in that population had significant muscle loss (sarcopenia), and that those with a higher body mass index (BMI) tended to have lower muscle quality despite higher quantity. They highlight the need for additional work to continue investigating how best to utilize computerized tomography (CT) scans to measure muscle mass and density to improve clinical outcomes.
“We hope that our work leads to future efforts for assessing patients’ muscle health—potentially using CT scans—as a strategy for identifying patients who may benefit from fitness or nutrition interventions, in order to enhance clinical outcomes,” said lead researcher Ryan D. Nipp, MD, MPH, Mass General Hospital Cancer Center and Harvard Medical School. “These findings build upon existing research showing unfavorable outcomes associated with poor muscle health in cancer patients, while also underscoring the added utility of assessing muscle radiodensity to measure muscle health. Muscle radiodensity provides information on the amount of intramuscular adipose tissue (fatty tissue within the muscle), and our findings suggest that higher BMI may contribute to that infiltration, resulting in lower muscle radiodensity.”
The researchers evaluated muscle data from the CT scans of 677 patients with advanced cancer who had an unplanned hospitalization between September 2014 and May 2016. The CT scans were performed as part of routine clinical care within 45 days before study enrollment, and results were compared against clinical outcomes as well as patient reported psychological assessments. Findings showed older, female patients tended to have lower muscle mass and radiodensity. Sixty-four percent of patients met the criteria for sarcopenia. Higher muscle radiodensity was significantly associated with better patient outcomes—including lower physical symptom burden and less depression and anxiety. However, it remains unclear whether poorer muscle radiodensity was a result of other symptoms that limit mobility, or vice versa.
“It’s possible that lower muscle radiodensity could lead to functional decline, and thus exacerbates physical and psychological symptoms,” said Dr. Nipp, who was a recipient of an NCCN Foundation® Young Investigators Award in 2016 for research on perioperative geriatric care intervention for older patients with gastrointestinal cancers undergoing surgical resection. “Conversely, patients with a higher symptom burden could have lower physical activity, which could have an effect on their muscle quality and quantity.”
“Increasing the quality of one’s weight through muscle development could be more important than simply trying to regain body weight to address cancer-related sarcopenia,” commented Scott J. Capozza, PT, MSPT, Board Certified Clinical Specialist in Oncologic Physical Therapy, Smilow Cancer Hospital and Yale Cancer Center, who was not involved with this research. “Skilled clinicians, such as oncology certified dietitians and physiotherapists, are able to develop evidence-based interventions to safely increase the quality of muscle mass. Having dietitians and physiotherapists included in the care team aligns with recommendations in the NCCN Guidelines for Survivorship. I look forward to future studies where these clinicians can be incorporated to address the quality of life and overall survival of patients with advanced cancers through nutrition, exercise, and physical rehabilitation.”
To read the entire study, visit JNCCN.org. Complimentary access to “Associations of Skeletal Muscle With Symptom Burden and Clinical Outcomes in Hospitalized Patients With Advanced Cancer” is available until June 10, 2021.
# # #
About JNCCN—Journal of the National Comprehensive Cancer Network More than 25,000 oncologists and other cancer care professionals across the United States read JNCCN—Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information about innovation in translational medicine, and scientific studies related to oncology health services research, including quality care and value, bioethics, comparative and cost effectiveness, public policy, and interventional research on supportive care and survivorship. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), review articles elaborating on guidelines recommendations, health services research, and case reports highlighting molecular insights in patient care. JNCCN is published by Harborside. Visit JNCCN.org. To inquire if you are eligible for a FREE subscription to JNCCN, visit http://www.nccn.org/jnccn/subscribe.aspx. Follow JNCCN on Twitter @JNCCN.
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg, Instagram @NCCNorg, and Twitter @NCCN.